Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has announced that it will report its first quarter 2022 financial results on May 5, 2022, at 8:30 a.m. ET. The company's management will host a conference call to discuss the results and company updates. Karyopharm is recognized for its pioneering work in cancer therapies, particularly with its lead compound, XPOVIO® (selinexor), which is approved in the U.S. for multiple oncology indications. The company continues to expand its presence in international markets, including Europe and Asia.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has announced that four abstracts related to selinexor clinical research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 3-7, 2022. Key presentations include an oral study on selinexor's effects in endometrial cancer and a poster discussion on its combination with ruxolitinib for myelofibrosis. This highlights Karyopharm's commitment to innovative treatments in oncology, focusing on cancers with significant unmet needs.
Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference, scheduled for April 14, 2022, at 9:30 a.m. ET. The virtual conference will include a live webcast accessible on Karyopharm's investor website, which will be available for replay for 90 days post-event. Karyopharm is recognized for its pioneering work in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, with its lead product, XPOVIO® (selinexor), approved in multiple cancer indications.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the approval of stock options for 58,600 shares and 36,900 restricted stock units (RSUs) to six newly-hired employees. These equity awards, granted on March 31, 2022, are part of the 2022 Inducement Stock Incentive Plan. Each stock option has an exercise price of $7.37 per share and will vest over four years. RSUs will also vest over four years, with a 25% vesting at each anniversary. These awards serve as inducements for new employees in line with Nasdaq Listing Rule 5635(c)(4).
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has appointed Dr. Reshma Rangwala as Chief Medical Officer, effective mid-April 2022. Dr. Rangwala brings over a decade of oncology experience, previously serving as CMO at Aravive and holding significant roles at Genmab and Merck. The company also announced the departure of co-founders Dr. Sharon Shacham and Dr. Michael Kauffman on May 31, 2022, although Dr. Shacham will remain on the Scientific Advisory Board. Karyopharm aims to accelerate its clinical development programs for its key therapeutic assets, XPOVIO and eltanexor.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the upcoming presentations of results from the Phase 3 SIENDO study of selinexor for advanced or recurrent endometrial cancer at the ESMO Virtual Plenary on March 17, 2022, and the SGO 2022 Annual Meeting on Women's Cancer from March 18-21, 2022. The SIENDO study is a multicenter, randomized trial involving 263 patients, aiming to demonstrate improved progression-free survival with selinexor maintenance therapy compared to placebo. The study represents an important step, as there are currently no approved maintenance therapies for this cancer type.
Karyopharm Therapeutics (Nasdaq: KPTI) announces the appointment of Elhan Webb as Senior Vice President of Investor Relations, effective March 14, 2022. Webb brings over 20 years of experience in investor relations and business development, having held roles at Rubius Therapeutics and Radius Health. CEO Richard Paulson emphasized her expertise in building investor relations to enhance Karyopharm's visibility in the market. The company is known for its lead compound, XPOVIO®, which is approved in multiple oncology indications.
Karyopharm Therapeutics (Nasdaq: KPTI) announced its senior management will engage in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 a.m. ET in Miami, Florida. This event highlights Karyopharm's pioneering role in developing cancer therapies, particularly with its lead product, XPOVIO® (selinexor), which is approved for multiple oncology indications.
Investors can access a live webcast of this chat and related slides via the company's investor site, with a replay available for 90 days post-event.
Karyopharm Therapeutics (KPTI) provided an update on its discussions with the FDA regarding its supplemental New Drug Application (sNDA) for selinexor, intended for advanced endometrial cancer. The FDA indicated that existing SIENDO study results might not justify an sNDA approval. Differing views on the study's clinical significance led to plans for a new randomized clinical trial focusing on p53 wild-type patients, with top-line data expected in H1 2024. The SIENDO study results will be presented at upcoming oncology conferences in March 2022.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on February 28, 2022, the approval of stock options for 168,500 shares and 112,200 restricted stock units (RSUs) to nine new employees. These awards are part of the 2022 Inducement Stock Incentive Plan and serve as an employment inducement per Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $10.33, vesting over four years, with specific conditions for immediate exercise upon a change in control or termination for good reason.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
